Login / Signup

Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.

Dmitry Y PushkarGeorge R KasyanKonstantin B KolontarevGeorgy G SharvadzeElvira I Mukhametshina
Published in: Neurourology and urodynamics (2019)
Imidafenacin is as effective as tolterodine for the treatment of OAB.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • clinical trial
  • phase ii study
  • double blind
  • study protocol
  • placebo controlled
  • squamous cell carcinoma
  • radiation therapy
  • combination therapy
  • locally advanced